SEC Company Response from Propanc Biopharma, Inc. (PPCB) (CIK 0001517681) (PPCB) — Feb 11, 2020
Propanc Biopharma, Inc. (PPCB) (CIK 0001517681)
Date: Feb. 11, 2020 · CIK: 0001517681 · Accession: 0001493152-20-001973
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235479
Letter
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC, 3124 Australia
February 11, 2020
VIA EDGAR
U.S. Securities & Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Re: Propanc Biopharma, Inc
Registration Statement on Form S-1/A
File No. 333-235479
Ladies and Gentlemen:
In accordance with Rule 461 of the Securities Act of 1933, as amended, Propanc Biopharma, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-captioned Registration Statement (the “Filing”) be accelerated so that it will be declared effective at 10:00 a.m. Eastern Time on Friday, February 14, 2020, or as soon thereafter as possible.
* * * *
Very
Truly Yours,
Propanc
Biopharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Propanc
Biopharma, Inc.
302,
6 Butler Street
Camberwell,
VIC, 3124 Australia
February
11, 2020
VIA
EDGAR
U.S.
Securities & Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Re:
Propanc
Biopharma, Inc
Registration
Statement on Form S-1/A
File
No. 333-235479
Ladies
and Gentlemen:
In
accordance with Rule 461 of the Securities Act of 1933, as amended, Propanc Biopharma, Inc. (the “Company”) hereby
respectfully requests that the effective date of the above-captioned Registration Statement (the “Filing”) be accelerated
so that it will be declared effective at 10:00 a.m. Eastern Time on Friday, February 14, 2020, or as soon thereafter as possible.
*
* * *
Very
Truly Yours,
Propanc
Biopharma, Inc.
/s/
James Nathanielsz.
James
Nathanielsz
Chief
Executive Officer